Literature DB >> 29378754

Repurposing Metformin for Cardiovascular Disease.

Graham Rena1, Chim C Lang1.   

Abstract

Entities:  

Keywords:  cardiovascular diseases; diabetes mellitus, type 2; metabolic syndrome; metformin; randomized controlled trial

Mesh：

Substances：

Year:  2018        PMID： 29378754     DOI： 10.1161/CIRCULATIONAHA.117.031735

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  27 in total

Review 1.  Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.

Authors:  Tanya Wilcox; Christophe De Block; Arthur Z Schwartzbard; Jonathan D Newman
Journal:  J Am Coll Cardiol       Date:  2020-04-28       Impact factor: 24.094

Review 2.  Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.

Authors:  Carolin Thomas; Lia Wurzer; Ernst Malle; Michael Ristow; Corina T Madreiter-Sokolowski
Journal:  Front Aging       Date:  2022-06-14

Review 3.  Benefits of Metformin in Attenuating the Hallmarks of Aging.

Authors:  Ameya S Kulkarni; Sriram Gubbi; Nir Barzilai
Journal:  Cell Metab       Date:  2020-04-24       Impact factor: 27.287

Review 4.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

5.  Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.

Authors:  Yechen Han; Hongzhi Xie; Yongtai Liu; Peng Gao; Xufei Yang; Zhujun Shen
Journal:  Cardiovasc Diabetol       Date:  2019-07-30       Impact factor: 9.951

6.  A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.

Authors:  Mohapradeep Mohan; Shaween Al-Talabany; Angela McKinnie; Ify R Mordi; Jagdeep S S Singh; Stephen J Gandy; Fatima Baig; Muhammad S Hussain; U Bhalraam; Faisel Khan; Anna-Maria Choy; Shona Matthew; John Graeme Houston; Allan D Struthers; Jacob George; Chim C Lang
Journal:  Eur Heart J       Date:  2019-11-01       Impact factor: 35.855

Review 7.  Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function.

Authors:  Mingying Deng; Dan Su; Suowen Xu; Peter J Little; Xiaojun Feng; Liqin Tang; Aizong Shen
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

8.  Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial.

Authors:  Joyce S Ramos; Lance C Dalleck; Caitlin E Keith; Mackenzie Fennell; Zoe Lee; Claire Drummond; Shelley E Keating; Robert G Fassett; Jeff S Coombes
Journal:  Int J Environ Res Public Health       Date:  2020-05-24       Impact factor: 3.390

9.  Metformin limits osteoarthritis development and progression through activation of AMPK signalling.

Authors:  Jun Li; Bin Zhang; Wei-Xiao Liu; Ke Lu; Haobo Pan; Tingyu Wang; Chun-do Oh; Dan Yi; Jian Huang; Lan Zhao; Guangzhi Ning; Cong Xing; Guozhi Xiao; Ru Liu-Bryan; Shiqing Feng; Di Chen
Journal:  Ann Rheum Dis       Date:  2020-03-10       Impact factor: 19.103

10.  Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.

Authors:  Eilon Ram; Jacob Lavee; Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman; Elad Maor; Tal Ovdat; Sergei Amunts; Leonid Sternik; Yael Peled
Journal:  Cardiovasc Diabetol       Date:  2019-09-16       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.